(NASDAQ:OCX),
IRVINE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) — Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend BTIG's MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, Utah. Oncocyte will host one-on-one meetings with interested investors.
Investors attending the conference wishing to schedule a meeting are encouraged to contact BTIG to schedule.
Event: BTIG's MedTech, Digital Health, Life Science & Diagnostic Tools Conference 2025
Dates: February 11-12, 2025
Location: Snowbird, Utah, USA
About Oncocyte
Oncocyte is a leading diagnostics technology company. The company's tests are designed to help provide clarity and confidence to physicians and their patients. VitaGraft(TM) is a clinical blood-based solid organ transplantation monitoring test. GraftAssure(TM) is a research use only (RUO) blood-based solid organ transplantation monitoring test. DetermaIO(TM) is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. DetermaCNI(TM) is a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients. For more information about Oncocyte, please visit https://oncocyte.com/. For more information about our products, please visit the following web pages:
VitaGraft Kidney(TM) – https://oncocyte.com/vitagraft-kidney/
VitaGraft Liver(TM) – https://oncocyte.com/vitagraft-liver/
GraftAssure(TM) – https://oncocyte.com/graftassure/
DetermaIO(TM) – https://oncocyte.com/determa-io/
DetermaCNI(TM) – https://oncocyte.com/determa-cni/
VitaGraft(TM), GraftAssure(TM), DetermaIO(TM), and DetermaCNI(TM) are trademarks of Oncocyte Corporation.
CONTACT:
Jeff Ramson
PCG Advisory
(646) 863-6893
jramson@pcgadvisory.com
